ACE-inhibition ameliorates vascular reactivity and delays diabetes outcome in NOD mice

Vascular Pharmacology

Volumn 49, Issue 2-3, 2008, Pages 84-90

  Bucci, Mariarosaria ^a   Roviezzo, Fiorentina ^a   Brancaleone, Vincenzo ^a   Di Lorenzo, Annarita ^a   Evangelista, Stefano ^b   Gori, Mario ^b   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Caveolin 1; NOD mice; Type I diabetes; Vascular functionality; Zofenopril

Indexed keywords

BETA ACTIN; CAVEOLIN 1; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; NITRATE; NITRITE; ZOFENOPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; GLUCOSURIA; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; VASCULAR DISEASE; VASODILATATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; CAPTOPRIL; CATTLE; CAVEOLIN 1; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENDOTHELIUM, VASCULAR; FEMALE; ISOPROTERENOL; MICE; MICE, INBRED NOD; NITRATES; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; NITROGEN OXIDES; PHENYLEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-2; VASOCONSTRICTION;

EID: 50849098826     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.06.002     Document Type: Article

References (52)

1. Ambrosioni E., Bacchelli S., Esposti D.D., and Borghi C. Anti-ischemic effect of angiotensin-converting enzyme inhibitors: a future therapeutic perspective. J. Cardiovasc. Pharmacol. 37 (2001) S3-S9
2. Ambrosioni E., Borghi C., and Magnani B. The effect of angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The survival of myocardial infarction long-term evaluation (SMILE) study investigators. New. Engl. J. Med. 332 (1995) 80-85
3. Atkinson M.A., and MacLaren N.K. The pathogenesis of insulin dependent diabetes. N. Engl. J. Med. 331 (1994) 1428-1436
4. Borghi C., and Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the survival of myocardial infarction long-term evaluation 2 (SMILE-2) study. Am. Heart. J. 145 (2003) 80-87
5. Borghi C., and Cicero A.F. Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. Vasc. Health Risk Manag. 2 4 (2006) 341-349
6. Borghi C., Ambrosioni E., and Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart. J. 153 3 (2007) 445.e7-445.e14
7. Borghi C., Bacchelli S., Degli Esposti D., and Ambrosioni E. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 26 (2003) 1862-1868
8. Bucci M., Roviezzo F., Brancaleone V., Lin M.I., Di Lorenzo A., Cicala C., Pinto A., Sessa W.C., Farneti S., Fiorucci S., and Cirino G. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Art. Thromb. Vasc. Biol. 24 (2004) 1-7
9. Buikema H., Monnink S.H.J., Tio R.A., Crijns H.J.G.M., de Zeeuw D., and van Gilst W.H. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br. J. Pharmacol. 130 (2000) 1999-2007
10. Chobanian A.V., Handenschild C.C., Nickerson C., and Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15 (1990) 327-331
11. Choi M.S., Jung U.J., Yeo J., Kim M.J., and Lee M.K. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab. Res. Rev. 24 1 (2008) 74-81 Jan-Feb
12. Cominacini L., Fratta Pasini A., Garbin U., Evangelista S., Crea E.A.G., Tagliacozzi D., Nava C., Davoli A., and Lo Cascio V. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 15 (2002) 891-895
13. Cushman D.W., Wang F.L., Fung W.C., Grover G.J., Harvey C.M., Scalese R.J., Mitch S.L., and DeForrest J.M. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 2 (1989) 115S-130S
14. Cushman D.W., Wang F.L., Fung W.C., Harvey C.M., and DeForrest J.M. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypertens. 2 4 (1989) 294-306
15. Daemen M., Lombardi D.M., Bosman F., and Schwartz S.M. Angiotensin II induces smooth muscle cell proliferation in the normal injured rat arterial wall. Circ. Res. 68 (1991) 450-456
16. de Nigris F., D'Armiento F.P., Somma P., Casini A., Sarlo F., Andreini A., Mansurto G., De Rosa G., Bonaduce D., Condorelli M., and Napoli C. Chronic treatment with sulphydryl angiotensin-converting enzyme inhibitors reduce susceptibility of LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int. J. Cardiol. 81 (2001) 107-115
17. Evangelista S., and Manzini S. Antioxudant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 33 (2005) 42-54
18. Evangelista S., Criscuoli M., and Manzini S. Tissue distribution of 14C a new angiotensin converting enzyme inhibitor with high affinity for the tissues in rats. In recent Research development in drug metabolism and disposition 1 (2002)
19. Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
20. Frascarelli S., Ghelardoni S., Ronca-Testoni S., and Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J. Cardiovasc. Pharmacol. 43 (2004) 294-299
21. Gonzales W., Fontaine V., Pueyo M.E., Laquay N., Messicka-Zeitoun D., Philippe N., Arnal J.F., Jacob M.P., and Michel J.B. Molecular plasticity of vascular wall during N(G)-nitro-l-arginine methyl ester-induced hypertension modulation of proinflammatory signals. Hypertension 36 (2000) 103-109
22. Gross V., Tank J., Partke H.J., Plehm R., Diedrich A., da Costa Goncalves A.C., Luft F.C., and Jordan J. Cardiovascular autonomic regulation in Non-Obese Diabetic (NOD) mice. Auton. Neurosci.: Bas. Clin. 138 (2008) 108-113
23. Han G., Wang R., Chen G., Wang J., Xu R., Feng J., Yu M., Wu X., Qian J., Shen B., and Li Y. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol. Lett. 115 2 (2008) 110-116
24. Hayek T., Attias J., Smith J., Breslow J.L., and Keidar S. Antiatherosclerotic and antioxidative effect of captopril in apolipoprotein E deficient mice. J. Cardiovasc. Pharmacol. 31 (1998) 540-544
25. Hayek T., Attias J., Coleman R., Brodsky S., Smith J., Breslow J.L., and Keidar S. The angiotensin-converting enzyme inhibitor, fosinopril and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc. Res. 44 (1999) 579-587
26. Je H.D., Gallant C., Leavis P.C., and Morgan K.G. Caveolin-1 regulates contractility in differentiated vascular smooth muscle. Am. J. Physiol. Heart. Circ. Physiol. 286 (2004) H91-H98
27. Jensen-Urstad K.J., Reichard P.G., Rosfors J.S., Lindblad L.E., and Jensen-Urstad M.T. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 45 (1996) 1253-1258
28. Keen H., Clark C., and Laasko M. Reducing the burden of diabetes: managing cardiovascular disease. Diabetes Res. Clin. Pract. 45 (1999) 153-160
29. Keidar S., Attias J., Coleman R., Wirth K., Scholkens B., and Hayek T. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J. Cardiovasc. Pharmacol. 35 (2000) 64-72
30. Kennon B., Petrie J.R., Small M., and Connell J.M.C. Angiotensin-converting enzyme gene and diabetes mellitus. Diabetic Med. 16 (1999) 448-458
31. Kikutani H., and Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51 (1992) 285-322
32. Kimura C., Oike M., Koyama T., and Ito Y. Impairment of endothelial nitric oxide production by acute glucose overload. Am. J. Physiol. Endocrinol. Metab. 280 1 (2001) E171-E178
33. Kowala M., Grove R., and Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 108 (1994) 61-72
34. Kventy J., Gregersen G., and Pedersen R.S. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 94 (2001) 89-94
35. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy: the collaborative study group. New. Engl. J. Med. 329 (1993) 1456-1462
36. Li J., Hirose N., Kawamura M., and Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 143 (1999) 315-326
37. Makino S., Kunimoto K., Murakoa Y., Mizushima K., Katagiri K., and Tochino Y. Breeding of a non-obese diabetic strain of mice. Jikken Dobutsu 29 (1980) 1-13
38. Misko T.P., Schilling R.J., Salvemini D., Moore W.M., and Currie M.G. A fluorimetric assay for the measurement of nitrite in biological samples. Anal. Biochem. 214 (1993) 11-16
39. Napoli C., Cicala C., D'Armiento F.P., Roviezzo F., Somma P., de Nigris F., Zuliani P., Bucci M., Aleotti M., Casini A., Franconi F., and Cirino G. Beneficial effect of ACE-inhibition with zofenopril on plaque formation and low density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen. Pharmacol. 33 (1999) 467-477
40. Niskanen L., Hedner T., Hansson L., Lanke J., and Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the captopril prevention project. Diabetes Care 24 (2001) 2091-2096
41. Oomen P.H.N., Jager J.K., Hoogenberg K., Dullaart R.P.F., Reitsma W.D., and Smit A.J. Capillary permeability is increased in normo- and microalbuminuric type I diabetic patients: amelioration by ACE-inhibition. Eur. J. Clin. Inv. 29 (1999) 1035-1040
42. Pasini A.F., Garbin U., Nava M.C., Stranieri C., Pellegrini M., Boccioletti V., Luchetta M.L., Fabrizzi P., Lo Cascio V., and Cominacini L. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am. Hypertens. 20 4 (2007) 443-450
43. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 982-988
44. Rolland P.H., Souchet T., Friggi A., Bodard H., Fye M.M., Ghiringhelli O., Garcon D., Charpiot P., Barlatier A., and Lafont H. Aorta viscoelasticity and arterial histopathology of atherosclerotic pigs treated by angiotensin converting enzyme inhibition. J. Hypertens. 9 (1991) S178-SS179
45. Sessa W.C. Regulation of endothelial nitric oxide in health and disease. Mem. Inst. Oswaldo Cruz 100 (2005) 15-18
46. Sreenan S., Pick A.J., Levisetti M., Baldwin A.C., Pugh W., and Polonsky K.S. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes 48 (1999) 989-996
47. Subissi A., Evangelista S., and Giachetti A. Preclinical profile of zofenopril: an angiotensin-converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 17 (1999) 115-133
48. Sun Y., and Mendelsohn F.A. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J. Cardiovasc. Pharmacol. 18 (1991) 478-486
49. The diabetes control and complications research group. The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329 (1993) 977-986
50. Thomsen L.L., Ching L.M., and Baguley B.C. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agent flavone-8-acetic and xanthenone-4-acetic acid. Cancer Res. 50 (1990) 6966-6970
51. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J. Clin. Pathol. 22 2 (1969) 158-161
52. Yusuf S., Sleght P., Pogue J., Bosch J., Davies R., and Dagenais G. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 342 (2000) 145-153